Tirzepatide after stopping: does the weight-loss success disappear?

In recent years, medicines such as Mounjaro have generated enormous excitement: several studies have reported striking effects on weight, blood sugar and cardiovascular risk. A major analysis of the active ingredient tirzepatide now raises an uncomfortable question: is the success largely wiped out once treatment stops?

How tirzepatide works in the body – and why weight falls so quickly

Tirzepatide belongs to a newer generation of medicines first developed for diabetes treatment. It acts on receptors for two gut hormones, GIP and GLP-1, which regulate hunger, fullness and blood sugar. Put simply, it substantially reduces appetite, helps the body use energy more sparingly and supports more stable pancreatic function.

In the large SURMOUNT-4 trial, adults with obesity or significant excess weight used the treatment for 36 weeks. They also received dietary counselling and followed a structured exercise programme. The results were:

• an average reduction in body weight of around 20 per cent
• improved blood sugar levels
• more favourable blood-fat levels, including lower “bad” LDL cholesterol
• lower blood pressure readings

For many people affected, such substantial weight loss means not only smaller clothing sizes, but also a markedly reduced risk of heart attack, stroke and diabetes.

For many specialists, this made tirzepatide appear to be a turning point in obesity treatment. However, the real test was still to come: what happens when the injections are stopped?

The second study phase: stopping treatment or continuing

After the first phase, researchers divided the participants into two groups. One group continued taking tirzepatide, while the other received an inactive placebo; neither group knew which treatment they were receiving. This “double-blind” approach is designed to prevent expectations from distorting the findings.

The central issue was whether the benefits would last after the medicine ended, or whether the body would effectively return to its starting point.

Rapid weight loss – rapid weight regain

The answer was disappointing. A clear pattern emerged in the placebo group: most participants regained a noticeable amount of weight.

• 82 per cent regained at least a quarter of the weight they had previously lost.
• Some people regained as much as three quarters of the kilograms lost.
• This happened within roughly a year of ending treatment.

As weight increased, many of the associated risks returned as well: LDL cholesterol rose, blood pressure climbed again and blood sugar control worsened. Those who regained the most weight were, across many measurements, almost back at their baseline levels – as though the 20 per cent weight reduction had never occurred.

The more weight participants regained after stopping treatment, the more their metabolic measurements deteriorated – a direct and measurable reversal.

For experts, this pattern fits the long-established reality of obesity: excess weight pushes up blood sugar, blood pressure and blood fats. When the weight comes off, these values improve; when it returns, the risks rise again.

Obesity as a chronic disease – is an injection really enough?

The findings place the current enthusiasm around weight-loss injections in a different context. Obesity has long been recognised as a chronic disease, much like high blood pressure or diabetes. With conditions of that kind, nobody seriously asks whether a medicine will simply become unnecessary after a few months.

Professional bodies are therefore openly discussing whether medicines such as tirzepatide should instead be regarded as long-term treatment. That would have several consequences:

• Patients would need to be prescribed treatment and supported over the long term.
• Health systems would have to meet very substantial costs for years.
• Doctors would need to select more carefully who is genuinely likely to benefit.

At the same time, psychologists such as Jane Ogden warn that many people barely alter their behaviour during treatment. Someone who no longer feels hungry because of an injection may cook less, stop planning meals and rely entirely on the medicine. When that “pharmacological shield” is removed, any learned structure can disappear with it.

Without lasting changes in everyday life, the medicine becomes a crutch – once it is taken away, the body stumbles back into old patterns.

Why stopping tirzepatide without a plan is so risky

The study highlights not only a medical challenge, but an organisational one too. Several experts are calling for a clear strategy for the period following any possible discontinuation. This should include:

• frequent weight monitoring
• personalised nutrition programmes
• supervised exercise, such as rehabilitation exercise or cardiac support groups
• psychological support where eating is strongly shaped by emotions

The first months after treatment ends are considered especially critical. Anyone left without support at that point can easily slip into a yo-yo pattern, with all the familiar consequences for the heart and metabolism.

Financial and ethical questions

Long-term use of medicines of this kind is expensive. Insurers and hospitals must weigh up the issues: how many heart attacks, strokes and cases requiring dialysis can be prevented over time? How does mortality change if people at risk maintain weight loss permanently? Only extended periods of observation will show whether widespread use is cost-effective.

There are ethical questions too. Should a very expensive medicine be used permanently for people who are “only” troubled by cosmetic concerns but do not yet have a high risk of disease? Or should it be reserved for those already facing serious secondary illnesses?

Special circumstances: family planning, pregnancy and sensitive groups

The researchers also point to indications from other work: when women stop the medicine shortly before pregnancy, they appear to face a higher risk of gestational diabetes and certain birth complications. The evidence remains limited, but many specialists now advise taking plans for children into account in treatment planning as early as possible.

For very young and very old patients, questions over long-term tolerability are even more pressing. People with pre-existing conditions affecting the stomach, intestines or pancreas are also among the groups that doctors need to assess particularly carefully.

What people can learn from the current tirzepatide data

Anyone considering tirzepatide or similar medicines should understand the new study not as a warning against the treatment itself, but as a warning against unrealistic expectations. The active ingredient has a powerful effect – but only while it remains in use.

A realistic plan could look like this:

• Begin treatment at a specialist practice or clinic.
• Build new routines alongside it: regular meal times, more physical activity and stress reduction.
• Monitor blood pressure, blood sugar and blood fats regularly.
• Only after behavioural changes are stable, reduce the dose cautiously – if that is appropriate at all.

Anyone who uses the medicine merely as a “quick fix” and then returns to their previous lifestyle risks falling into the same trap as with crash diets: the weight comes back, often with interest, and the metabolism suffers twice over.

In the long term, a combined approach is likely to prevail: medicines such as tirzepatide as a powerful tool, embedded within a closely supervised programme of nutrition, exercise and psychological support. This increases the likelihood that not only the scales, but also the heart and blood vessels, will benefit sustainably.